Roche snaps up rest of Foundation Medicine for $2.4bn
Roche is buying the shares it does not already own in US molecular information company Foundation Medicine (FMI), in a deal valued at $2.4 billion.
Read More
Tag: FMI
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
